CVS to expand pharmacy business with $10.1 billion Omnicare buy
Reuters
Published May 21, 2015 11:20AM ET
CVS to expand pharmacy business with $10.1 billion Omnicare buy
(Reuters) - Drugstore operator CVS Health Corp (N:CVS) said Thursday it will spend $10.1 billion to buy Omnicare Inc (N:OCR), a company that supplies prescription medicines to nursing, assisted living and other healthcare facilities.
The move gives CVS, the second-largest U.S. drugstore operator, access to the older, sicker U.S. population and builds on its specialty pharmacy, which provides drugs to people with expensive chronic conditions such as rheumatoid arthritis.
CVS said it expects the deal to add about 20 cents to adjusted earnings per share in 2016. The deal also includes debt of about $2.3 billion, the companies said.
The pharmaceutical sector has been consolidating as companies look to beef up and bargain for lower prices from both drug manufacturers and the three largest U.S. drug distributors.
"There's a lot of purchasing scale. There's a lot more volume. They could renegotiate their supply contracts given the volume," said FBR analyst Steven Halper.
In addition to its drugstore chain and mail-order sales, CVS is the second-largest pharmacy benefit manager in the United States, securing pricing for big employers and government plans.
CVS offered $98 per Omnicare share, representing a premium of 4 percent to the closing price Wednesday of Omnicare, the top U.S. provider of pharmacy services to the elderly.
The offer is at a nearly 21 percent premium to Omnicare's April 21 close, a day before Bloomberg reported that the company was exploring a sale.
Shares of Omnicare, rose 1.5 percent to $96 while CVS was up 2.8 percent at $104.08.
FOLLOWS OTHER DEALS
Bloomberg first reported Wednesday that CVS was nearing a deal to buy Omnicare.
Speculation has mounted of more pharmacy-industry consolidation as others have tied up, and the field of companies involved in drug distribution, sales or management has shrunk.
Health insurer UnitedHealth Group Inc (N:UNH) agreed to buy Catamaran Corp (O:CTRX) (TO:CCT) for about $12.8 billion in March. Rite Aid Corp (N:RAD) bought pharmacy benefit manager EnvisionRx for about $2 billion in February. Last year, pharmacy Walgreen tied up with European pharmacy and drug distribution company Boots Alliance.
CVS said it secured $13 billion in financing from Barclays (LONDON:BARC) for the deal, which is expected to close near the end of 2015.
Get The News You Want
Barclays and Evercore are CVS's financial advisers, while Bank of America Merrill Lynch (NYSE:BAC) and Centerview Partners advised Omnicare. CVS's legal adviser is Sullivan & Cromwell LLP, while White & Case LLP served as Omnicare's legal counsel.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.